Last reviewed · How we verify
Baricitinib Oral Tablet
Baricitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.
Baricitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation. Used for Rheumatoid arthritis, Atopic dermatitis, Alopecia areata.
At a glance
| Generic name | Baricitinib Oral Tablet |
|---|---|
| Also known as | LY3009104, Olumiant, Arm B |
| Sponsor | Azienda Ospedaliero, Universitaria Pisana |
| Drug class | JAK inhibitor |
| Target | JAK1, JAK2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Baricitinib selectively inhibits JAK1 and JAK2 enzymes, which are intracellular kinases involved in the signaling of multiple inflammatory cytokines including interferons and interleukins. By blocking JAK-STAT pathway signaling, the drug suppresses the proliferation and activation of immune cells, reducing systemic inflammation and autoimmune responses. This mechanism makes it effective in conditions driven by dysregulated Th1 and Th17 cell responses.
Approved indications
- Rheumatoid arthritis
- Atopic dermatitis
- Alopecia areata
- COVID-19 (investigational)
Common side effects
- Upper respiratory tract infection
- Elevated cholesterol
- Herpes zoster reactivation
- Elevated liver enzymes
- Headache
- Nausea
Key clinical trials
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis (PHASE1)
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID (PHASE3)
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) (PHASE3)
- Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) (PHASE2)
- Baricitinib for Reduction of HIV - CNS (PHASE2)
- Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study (PHASE2)
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baricitinib Oral Tablet CI brief — competitive landscape report
- Baricitinib Oral Tablet updates RSS · CI watch RSS
- Azienda Ospedaliero, Universitaria Pisana portfolio CI